Ariel is a precision medicine company focused on complex diseases leveraging proprietary diagnostics and analytics to develop first in disease therapeutics. Our initial focus is pancreatitis, an $8 B per year revenue opportunity. There is substantial evidence that our phase II ready lead candidate will be effective in this population.